Drugs / AZD0754
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06267729 | Mar 2024 → Nov 2026 expected | metastatic prostate carcinoma | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD0754 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06267729 ↗ |
| Modality | Cell therapy | “a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2” NCT06267729 ↗ |
| Route | Intravenous | “administered intravenously” NCT06267729 ↗ |
| Target | STEAP2 | “Directed Against STEAP2” NCT06267729 ↗ |